Eli Lilly and CompanyLLY
NYQ • Healthcare
$1179.11
P/E
41.77
PEG
0.25
FCF Yield
0.6%
Rev Growth YoY
+55.5% YoY
Gross Margin
81.9%
Health Score
8/10
D/E Ratio
1.39
Confidence
MEDIUM
Business Snapshot
Eli Lilly is a dominant player in the drug manufacturing industry, generating revenue primarily through a portfolio of blockbuster pharmaceuticals, including diabetes and obesity treatments such as Mounjaro and Zepbound. Operating within the highly regulated and R&D-intensive healthcare sector, Lilly holds a commanding position as a top-tier global pharmaceutical innovator with a market capitalisation of $1.05 trillion, classifying it as a mega-cap company and one of the most valuable healthcare firms globally. The company's massive financial scale is underscored by trailing twelve-month (TTM) revenue of $72.25 billion, reflecting its ability to commercialise high-demand therapies at significant scale. A defining characteristic is its leadership in the rapidly expanding GLP-1 receptor agonist market, a therapeutic category with substantial long-term demand and high barriers to entry from competitors.
Financial Health
Eli Lilly's profitability is exceptional, with a gross margin of 81.9% and a net margin of 35.0%, though the gross margin has slightly contracted from 82.5% in the prior year. The balance sheet is moderately leveraged with a debt-to-equity ratio of 1.39x, which is manageable given the company's high earnings power, while the current ratio of 1.5x indicates adequate short-term liquidity...
Risk Assessment
- VALUATION — P/E of 41.77x is nearly double the sector average of 22x, pricing in perfection and leaving little room for execution missteps.
- VALUATION DIVERGENCE — A Python DCF estimate of $318.06 per share is dramatically below the current price of $1,179.11, indicating the market is pricing in a growth trajectory that far exceeds a standard 20% FCF growth assumption.
- REVENUE DECELERATION — While YoY revenue growth is a blistering 55.5%, the QoQ increase of just 2.6% signals a potential deceleration from the peak growth rate, which could disappoint momentum-driven investors.
- TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed.
- INSIDER ACTIVITY — Over the last 90 days, insiders have conducted 2 sales with 0 buys, a net-selling pattern that can signal a perceived peak in the stock's valuation....
Eli Lilly's profitability is exceptional, with a gross margin of 81.9% and a net margin of 35.0%, though the gross margin has slightly contracted from 82.5% in the prior year. The balance sheet is moderately leveraged with a debt-to-equity ratio of 1.39x, which is manageable given the company's high earnings power, while the current ratio of 1.5x indicates adequate short-term liquidity. Free cash flow stands at $5.96 billion, a strong absolute figure, though the free cash flow (FCF) yield of 0.6% is low due to the company's massive market valuation. Overall, Lilly possesses a robust financial profile with industry-leading margins, significant cash generation for reinvestment into R&D and capacity expansion, and sufficient liquidity to service its debt obligations.
- VALUATION — P/E of 41.77x is nearly double the sector average of 22x, pricing in perfection and leaving little room for execution missteps. - VALUATION DIVERGENCE — A Python DCF estimate of $318.06 per share is dramatically below the current price of $1,179.11, indicating the market is pricing in a growth trajectory that far exceeds a standard 20% FCF growth assumption. - REVENUE DECELERATION — While YoY revenue growth is a blistering 55.5%, the QoQ increase of just 2.6% signals a potential deceleration from the peak growth rate, which could disappoint momentum-driven investors. - TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed. - INSIDER ACTIVITY — Over the last 90 days, insiders have conducted 2 sales with 0 buys, a net-selling pattern that can signal a perceived peak in the stock's valuation.
Unlock the full AI report
Full 8-section analysis includes:
Metric deep-dives